Factors related with prostaglandin associated periorbitopathy (PAP) in glaucoma patients

Not Applicable

Recruiting

• Conditions: prostaglandin associated periorbitopathyglaucomaocular hypertension; prostaglandin associated periorbitopathy; glaucoma; ocular hypertension; risk factors; protective factors

• Registration Number: TCTR20141011001
• Lead Sponsor: Ratchadapiseksompotch Fund

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2014-10-11
• Study Completion: 2015-04-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

Glaucoma or ocular hypertension patients
Use prostaglandin analogs for controlling IOP
Continue using for at least 3 months

Exclusion Criteria

Patients who have history of intraocular or extraocular surgery except cataract, filtering surgery, and laser treatment
Patients who use other glaucoma drugs other than PGAs except timolol within 6 months
Patients who have generalized lipodystrophy

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Risk factors and protective factors none Photographs

Secondary Outcome Measures

Name	Time	Method
Prevalence none none